相关费用:选择性费用 ︾PAGE CHARGES
For research, review, and mini-review articles, the publication charges are US $490 (inclusive of limited-time open access) per article.
Bentham Science offers a 50% discount off all page charges for manuscripts of all corresponding authors who reside in countries which are categorized as low-income economies by the World Bank. To see if you qualify to the discount, please refer to the complete list of these countries(https://www.benthamscience.com/pages/special-discount)
OPEN ACCESS PLUS (GOLD OPEN ACCESS)
Bentham Science also offers authors the option of “Open Access Plus (Gold Open Access)” for publishing their articles. The article processing charges are US $3695 per article for general submissions and US $1900 per article for those published within thematic issues.
QUICK TRACK PUBLICATION
For this journal an optional fast publication fee-based service called QUICK TRACK is available to authors for their submitted manuscripts.
The author will be initially charged a small fee on receipt of the agreement form for Quick Track publication to partially cover the initial costs incurred for expedited processing of the submitted manuscript. Later, the full Quick Track publication fee (US $4615 per composed page charges) will be payable in advance, after acceptance of the manuscript, before online publication of the article. However, if the article is rejected at the peer-review stage, then the US $4615 per composed page charges will not be charged.
出版地址:BENTHAM SCIENCE PUBL LTD , EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, SHARJAH, U ARAB EMIRATES, 1200 BR
期刊简介:Recent Patents on Anti-Cancer Drug Discovery《抗癌药物发现最新专利》(双月刊). Recent Patents on Anti-Cancer Drug Discovery publishes review/mini review and research articles that reflect or deal with studies in relation to a patent, application of reported patents in a study, discussion of comparison of results regarding application of a given patent, etc., and also guest edited thematic issues on recent patents in the field of anti-cancer drug discovery e.g. on novel bioactive compounds, analogs, targets & predictive biomarkers & drug efficacy biomarkers.